Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Moderna's mRNA-1345 RSV vaccine is proving its worth in the real world. A new study of nearly 150,000 veterans found the vaccine cut RSV-related hospitalizations by over 80% at 24 weeks. Effectiveness was highest in younger seniors but declined with age, giving clinicians useful data to guide vaccination conversations.
Moderna's mRNA-1345 RSV vaccine is delivering real-world results. A large study published in JAMA Network Open analyzed nearly 150,000 veterans (median age 73) and found that the vaccine offered meaningful protection against RSV infections, ER visits, and hospitalizations over a 24-week period. The Veterans Health Administration had preferentially adopted mRNA-1345, making this one of the first major community-setting effectiveness analyses for this specific vaccine.
The findings largely align with earlier clinical trial data, though researchers note that direct comparisons are tricky due to differences in patient populations, RSV seasons, and outcome definitions. One notable finding: effectiveness dropped significantly in the oldest patients, raising questions about how well the vaccine holds up in the 80+ age group.
By the Numbers:
Why it matters: With multiple RSV vaccines now available, this real-world data helps clinicians make more informed recommendations — especially for older, higher-risk patients who stand to benefit most from protection against severe RSV illness.